Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lung cancer in 2014: optimizing lung cancer treatment approaches.

Literature DB >> 25533943

Lung cancer in 2014: optimizing lung cancer treatment approaches.

Abstract

In 2014, developments in our understanding of escape signalling circuits implicated in resistance to targeted agents in patients with lung cancer have led to improvements in tackling such resistance. The potential role for PET in the management of erlotinib therapy, novel combination therapies and pharmacogenomic-driven individualization of platinum-based chemotherapy represent other key advances.

Entities: Chemical Disease Species

Mesh：

Year: 2014 PMID： 25533943 DOI： 10.1038/nrclinonc.2014.225

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

9 in total

1. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.

Authors: Ho-June Lee; Guanglei Zhuang; Yi Cao; Pan Du; Hyo-Jin Kim; Jeff Settleman
Journal: Cancer Cell Date: 2014-07-24 Impact factor: 31.743

2. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

Authors: Martin Reck; Rolf Kaiser; Anders Mellemgaard; Jean-Yves Douillard; Sergey Orlov; Maciej Krzakowski; Joachim von Pawel; Maya Gottfried; Igor Bondarenko; Meilin Liao; Claudia-Nanette Gann; José Barrueco; Birgit Gaschler-Markefski; Silvia Novello
Journal: Lancet Oncol Date: 2014-01-09 Impact factor: 41.316

3. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.

Authors: Weiwen Fan; Zhe Tang; Lihong Yin; Bei Morrison; Said Hafez-Khayyata; Pingfu Fu; Honglian Huang; Rakesh Bagai; Shan Jiang; Adam Kresak; Scott Howell; Amit Vasanji; Chris A Flask; Balazs Halmos; Henry Koon; Patrick C Ma
Journal: Cancer Res Date: 2011-05-09 Impact factor: 12.701

4. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors: Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal: Lancet Oncol Date: 2014-08-27 Impact factor: 41.316

5. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.

Authors: Sizhi Paul Gao; Kevin G Mark; Kenneth Leslie; William Pao; Noriko Motoi; William L Gerald; William D Travis; William Bornmann; Darren Veach; Bayard Clarkson; Jacqueline F Bromberg
Journal: J Clin Invest Date: 2007-12 Impact factor: 14.808

6. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.

Authors: Rui Li; Zhongliang Hu; Shi-Yong Sun; Zhuo G Chen; Taofeek K Owonikoko; Gabriel L Sica; Suresh S Ramalingam; Walter J Curran; Fadlo R Khuri; Xingming Deng
Journal: Mol Cancer Ther Date: 2013-07-26 Impact factor: 6.261

7. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

Authors: T Moran; J Wei; M Cobo; X Qian; M Domine; Z Zou; I Bover; L Wang; M Provencio; L Yu; I Chaib; C You; B Massuti; Y Song; A Vergnenegre; H Lu; G Lopez-Vivanco; W Hu; G Robinet; J Yan; A Insa; X Xu; M Majem; X Chen; R de Las Peñas; N Karachaliou; M A Sala; Q Wu; D Isla; Y Zhou; N Baize; F Zhang; J Garde; P Germonpre; S Rauh; H ALHusaini; M Sanchez-Ronco; A Drozdowskyj; J J Sanchez; C Camps; B Liu; R Rosell; B Colinet; J De Grève; P Germonpré; H Chen; X Chen; J Du; Y Gao; J Hu; W Hu; W Kong; L Li; R Li; X Li; B Liu; J Liu; H Lu; X Qian; W Ren; Y Song; L Wang; J Wei; L Wen; Q Wu; X Xiao; X Xu; J Yan; J Yang; M Yang; Y Yang; J Yin; C You; L Yu; X Yue; F Zhang; J Zhang; Y Zhou; L Zhu; Z Zou; N Baize; P Bombaron; C Chouaid; E Dansin; P Fournel; G Fraboulet; R Gervais; S Hominal; S Kahlout; H Lecaer; H Lena; J LeTreut; C Locher; O Molinier; I Monnet; G Oliviero; G Robinet; R Schoot; P Thomas; A Vergnènegre; G Berchem; S Rauh; H Al Husaini; F Aparisi; E Arriola; I Ballesteros; I Barneto; R Bernabé; A Blasco; J Bosch-Barrera; I Bover; V Calvo de Juan; C Camps; E Carcereny; S Catot; M Cobo; R De Las Peñas; M Dómine; E Felip; M R García-Campelo; C García-Girón; R García-Gómez; R Garcia-Sevila; J Garde; A Gasco; J Gil; J L González-Larriba; S Hernando-Polo; E Jantus; A Insa; D Isla; B Jiménez; P Lianes; R López-López; A López-Martín; G López-Vivanco; J A Macias; M Majem; J L Marti-Ciriquian; B Massuti; R Montoyo; D Morales-Espinosa; T Morán; M A Moreno; C Pallares; M Parera; R Pérez-Carrión; R Porta; M Provencio; N Reguart; R Rosell; F Rosillo; M A Sala; J M Sanchez; I Sullivan; J Terrasa; J M Trigo; J Valdivia; N Viñolas; S Viteri; M Botia-Castillo; J L Mate; M Perez-Cano; J L Ramirez; B Sanchez-Rodriguez; M Taron; M Tierno-Garcia; E Mijangos; J Ocaña; E Pereira; J Shao; X Sun; R O'Brate
Journal: Ann Oncol Date: 2014-08-27 Impact factor: 32.976

Review 8. Genetics and biomarkers in personalisation of lung cancer treatment.

Authors: Rafael Rosell; Trever G Bivona; Niki Karachaliou
Journal: Lancet Date: 2013-08-24 Impact factor: 79.321

9. [¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.

Authors: Mammar Hachemi; Olivier Couturier; Laurent Vervueren; Pacôme Fosse; Franck Lacœuille; Thierry Urban; José Hureaux
Journal: PLoS One Date: 2014-02-05 Impact factor: 3.240

9 in total

31 in total

1. Detection of circulating tumor cells in non-small cell lung cancer.

Authors: Gerhard Hamilton; Barbara Rath
Journal: J Thorac Dis Date: 2016-06 Impact factor: 2.895

2. MiR-590 suppresses the progression of non-small cell lung cancer by regulating YAP1 and Wnt/β-catenin signaling.

Authors: X Hao; A Su
Journal: Clin Transl Oncol Date: 2022-01-15 Impact factor: 3.405

3. Increased expression of lncRNA ZEB1-AS1 in non-small cell lung cancer is associated with poor prognosis.

Authors: Jing Xie; Yufeng Wu; Xiaojie Bian; Dongqin Chen; Qi Gui; Jianan Huang
Journal: Int J Clin Exp Pathol Date: 2018-07-01

4. Effects of X-radiation on lung cancer cells: the interplay between oxidative stress and P53 levels.

Authors: Fernando Mendes; Tiago Sales; Cátia Domingues; Susann Schugk; Ana Margarida Abrantes; Ana Cristina Gonçalves; Ricardo Teixo; Rita Silva; João Casalta-Lopes; Clara Rocha; Mafalda Laranjo; Paulo César Simões; Ana Bela Sarmento Ribeiro; Maria Filomena Botelho; Manuel Santos Rosa
Journal: Med Oncol Date: 2015-11-18 Impact factor: 3.064

5. Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study.

Authors: Yuan Feng; Jihong Zhou; Zhanhua Li; Ying Jiang; Ying Zhou
Journal: PLoS One Date: 2016-09-14 Impact factor: 3.240

6. Micro RNA-98 interferes with expression interleukin-10 in peripheral B cells of patients with lung cancer.

Authors: Yun Li; Jian Rong; Jie Qin; Jin-Yuan He; Hui-Guo Chen; Shao-Hong Huang
Journal: Sci Rep Date: 2016-09-08 Impact factor: 4.379

7. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.

Authors: Giuseppe Roscilli; Claudia De Vitis; Fabiana Fosca Ferrara; Alessia Noto; Emanuela Cherubini; Alberto Ricci; Salvatore Mariotta; Enrico Giarnieri; Maria Rosaria Giovagnoli; Maria Rosaria Torrisi; Francesca Bergantino; Susan Costantini; Francesca Fenizia; Matilde Lambiase; Luigi Aurisicchio; Nicola Normanno; Gennaro Ciliberto; Rita Mancini
Journal: J Transl Med Date: 2016-02-29 Impact factor: 5.531